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Abstract: Aspalathin, a C-glucosyl dihydrochalcone, has previously been shown to protect
cardiomyocytes against hyperglycemia-induced shifts in substrate preference and subsequent apoptosis.
However, the precise gene regulatory network remains to be elucidated. To unravel the mechanism
and provide insight into this supposition, the direct effect of aspalathin in an isolated cell-based
system, without the influence of any variables, was tested using an H9c2 cardiomyocyte model.
Cardiomyocytes were exposed to high glucose (33 mM) for 48 h before post-treatment with or
without aspalathin. Thereafter, RNA was extracted and RT2 PCR Profiler Arrays were used to
profile the expression of 336 genes. Results showed that, 57 genes were differentially regulated in
the high glucose or high glucose and aspalathin treated groups. Search Tool for the Retrieval of
Interacting Genes/Proteins (STRING) analysis revealed lipid metabolism and molecular transport as
the biological processes altered after high glucose treatment, followed by inflammation and apoptosis.
Aspalathin was able to modulate key regulators associated with lipid metabolism (Adipoq, Apob, CD36,
Cpt1, Pparγ, Srebf1/2, Scd1 and Vldlr), insulin resistance (Igf1, Akt1, Pde3 and Map2k1), inflammation
(Il3, Il6, Jak2, Lepr, Socs3, and Tnf13) and apoptosis (Bcl2 and Chuk). Collectively, our results suggest
that aspalathin could reverse metabolic abnormalities by activating Adipoq while modulating the
expression of Pparγ and Srebf1/2, decreasing inflammation via Il6/Jak2 pathway, which together with
an observed increased expression of Bcl2 prevents myocardium apoptosis.
Keywords: diabetes mellitus; hyperglycemia; cardiomyopathy; lipotoxicity; polyphenols; aspalathin
1. Introduction
During the last decade, there has been considerable interest in the use of plant-derived
polyphenols as nutraceuticals to slow down the progression of metabolic diseases [1,2].
Aspalathus linearis (commonly known as rooibos) is a rich source of plant polyphenols with known
health promoting properties. In addition to reversing ischemia/reperfusion injury in the isolated
perfused rat heart [3], rooibos has been shown to improve both lipotoxicity and oxidative stress
in diabetic individuals at risk of developing cardiovascular disease [4,5]. Furthermore, literature
has indicated that polyphenols specific to rooibos may present strong ameliorative properties
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against diabetes mellitus and its associated complications [6–8]. Of note, aspalathin, a C-glucosyl
dihydrochalcone found uniquely in rooibos, has displayed an even greater potency to prevent
diabetes-induced cardiovascular complications [9–11]. For example, a fermented rooibos extract
containing abundant levels of aspalathin protected primary isolated rat cardiomyocytes from
experimentally induced oxidative stress and apoptosis [9]. Moreover, recent data from our
laboratory demonstrated that aspalathin was able to protect H9c2 cardiomyocytes against high
glucose-induced shifts in substrate preference by decreasing fatty acid uptake and oxidation,
inferring that aspalathin might act as a fatty acid oxidation modulator in the heart of the
diabetic individuals. Furthermore, we demonstrated that aspalathin treatment was able to prevent
mitochondrial membrane depolarization and subsequent apoptosis by reducing DNA nick formation,
while increasing Bcl2/Bax ratio [10].
Altered substrate metabolism and reduced myocardial production of adenosine triphosphate
(ATP) are main contributors to the development of left ventricular dysfunction, a characteristic
of the diabetic cardiomyopathy (DCM). Apart from altered substrate metabolism, DCM has been
associated with an enhanced intracellular lipid accumulation as observed in hearts obtained from
leptin-receptor-deficient diabetic mice (Leprdb/db) and diabetic patients with cardiomyopathy [12–14].
The precise molecular mechanisms associated with the etiology of DCM remains to be fully elucidated.
However, gene regulatory pathways of peroxisome proliferator-activated receptor α or γ (Ppparα/γ)
and sterol regulatory element-binding protein 1c (Srerbp1c) have been implicated as important
molecular switches that regulate shifts in substrate preference and subsequent lipid accumulation
in the heart of diabetic patients [15,16]. Notably, in a study done by Marfella et al. [15], increased
expression of PPARγ and Srebf1c was observed in pressure overload-hearts from diabetic patients.
Similarly, in a study done by Son et al. [16], transgenic mice overexpressing PPARγ in the myocardium
showed increased expression of fatty acid oxidation and lipid storage genes, inferring that
hyperglycemia and impaired lipid accumulation play an important role in the development of DCM.
It would therefore be of interest to use RT2 PCR Profiler Arrays to predict the possible transcriptional
mechanisms used by aspalathin to protect the myocardium against the development of high
glucose-induced cardiomyopathy. Therefore, an isolated H9c2 model was employed to unravel
this mechanism. Results obtained showed that aspalathin protected Leprdb/db mice against raised levels
of total cholesterol, triglycerides and low-density lipoprotein (LDL) possibly by modulating genes
associated with high glucose-induced lipotoxicity, fatty acid oxidation, insulin resistance, inflammation
and apoptosis as demonstrated in H9c2 cardiomyocytes.
2. Results and Discussion
2.1. Effect of Aspalathin on Lipid Profiles
Increased morbidity observed in type 2 diabetes individuals is primarily associated with heart failure,
with lipotoxicity being the key pathological mechanism underlying the diabetic condition [5,10,12,14].
The ability of aspalathin to improve lipoprotein clearance was assessed by performing a total lipid
profile on mice treated with two dose levels of aspalathin for six weeks (Table 1). The control
received no aspalathin. The diabetic untreated control Leprdb/db_UC mice had increased body weight,
plasma glucose levels (fasting plasma glucose (FPG)), insulin, homeostatic model assessment-insulin
resistance (HOMA-IR) levels with associated elevated triglycerides, total cholesterol, LDL and high
density lipoprotein (HDL) levels when compared to the nondiabetic lean untreated control Leprdb/+_UC
group (Table 1). Aspalathin treatment, was able to dose–dependently modulate this condition as the
effect of the high dose was greater than either the low dose aspalathin or the metformin treated groups.
However, similar to metformin, aspalathin treatment did not affect HDL cholesterol or reduce
raised FPG levels. Inferring that aspalathin treatment improves serum lipid profiles and cardiac
risk associated with an increased LDL (Table 1). However, it is known that Leprdb/db mice display
a defective catabolism for the major apolipoprotein A-1 (Apoa1), leading to increased HDL and
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atherosclerosis protection [13]. Similarly, the failure of aspalathin to lower FPG levels can be due to
factors such as duration of treatment since previous studies have demonstrated its effectiveness when
used at a shorter time interval [7,8]. However, based on our model to induce cardiomyopathy between
9 and 10 weeks, the disease was at an advance stage with chronically elevated blood glucose levels,
which resulted in increased oxidative stress and subsequent cardiac damage. Thus, we did not expect
either metformin or aspalathin to have an effect on hyperglycemia.
Cardiac failure has been associated with an enhanced intracellular lipid accumulation [12–14].
In the current study, we showed that aspalathin treatment significantly lowered plasma lipid levels in
Leprdb/db mice. To provide insight into the molecular mechanisms by which aspalathin improved lipid
profiles in Leprdb/db mice, an isolated in vitro H9c2 cell-based system was used to investigate the effect
of aspalathin on lipotoxicity in the heart. All subsequent gene expression profiling experiments were
done using this model.
Table 1. Effect of aspalathin on blood lipid profiles and HOMA-IR.
Lipid Profile
Parameter Lepr
db/+_UC Leprdb/db_UC Leprdb/db_MET Leprdb/db_ASP_LD Leprdb/db_ASP_HD
Body weight
(g) 27.1±0.33 37.9 ± 0.82 *** 38.0 ± 0.61 *** 37.7 ± 0.74 *** 35.0 ± 0.99 ***
,#
Total cholesterol
(mmol/L) 2.4 ± 0.09 3.5 ± 0.18 *** 2.9 ± 0.18 *
,# 3.2 ± 0.18 ** 2.7 ± 0.24 #
LDL
(mmol/L) 0.1 ± 0.06 0.4 ± 0.07 * 0.2 ± 0.04
# 0.2 ± 0.05 0.1 ± 0.04 ##
HDL
(mmol/L) 1.7 ± 0.06 2.5 ± 0.10 *** 2.2 ± 0.13 ** 2.3 ± 0.13 ** 2.3 ± 0.14 **
Triglycerides
(mmol/L) 0.9 ± 0.04 3.2 ± 0.38 *** 2.3 ± 0.46 * 2.6 ± 0.19 *** 2.3 ± 0.28 **
Insulin
(ng/mL) 0.4 ± 0.09 1.9 ± 1.02 1.1 ± 0.22 1.5 ± 0.34 0.7 ± 0.10
FPG
(mmol/L) 5.6 ± 0.29 21.2 ± 1.34 *** 18.1 ± 1.68 *** 22.2 ± 1.50 *** 22.0 ± 1.41 ***
HOMA-IR 0.1 ± 0.01 0.6 ± 0.28 0.3 ± 0.05 0.4 ± 0.07 0.2 ± 0.03
Results are the mean ± SEM, with each treatment group containing six mice. * p < 0.05, ** p < 0.001, *** p < 0.0001
versus heterozygous leptin-receptor-deficient (Lepr) nondiabetic lean littermate untreated controls (Leprdb/+_UC);
# p < 0.05, ## p < 0.001 versus homozygous leptin-receptor-deficient diabetic mice untreated controls (Leprdb/db_UC).
Leprdb/+_ASP_LD: diabetic mice treated with low dose aspalathin (13 mg/kg), Leprdb/+_ASP_HD: diabetic mice
treated with high dose aspalathin (130 mg/kg), Leprdb/+_MET: diabetic mouse treated with metformin (150 mg/kg),
FPG: fasting plasma glucose, HDL: high density lipoprotein, HOMA-IR: homeostasis model assessment:
insulin resistance, LDL: low density lipoprotein.
2.2. In Vitro Effects of Aspalathin
To confirm our in vivo findings and to decipher the molecular mechanism used by aspalathin to
modulate substrate availability and improve hyperglycemia-associated lipotoxicity, gene expression
profiling was performed on H9c2 cardiomyocytes exposed to high glucose. Of the 336 genes assessed,
57 genes (17%) were differentially expressed and of these, 45 and 12 genes (79% and 21%) were
hyper-expressed in the high glucose and aspalathin treated groups, respectively (Table 2). Search Tool
for the Retrieval of Interacting Genes/Proteins data analysis confirmed that aspalathin treatment
largely improved the expression of genes involved in metabolic processes, identifying fatty acid and
lipid metabolism as the top two regulatory processes (Figure 1).
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Table 2. Effect of aspalathin on the transcriptional profile of genes involved in metabolic processes.
Gene Name Gene Symbol
Gene Fold Regulation
High Glucose (33 mM) Aspalathin (1 µM)
Lipid metabolism
ATP-binding cassette, subfamily A (ABC1), member 1 Abca1 2.0776 −1.1921
Acyl-Coenzyme A dehydrogenase, C-2 to C-3 short chain Acads −1.6611 −2.425
Acyl-CoA thioesterase 2 Acot2 2.8239 −1.2178
Acyl-Coenzyme A oxidase 2, branched chain Acox2 2.0959 1.8895
Acyl-CoA synthetase bubblegum family member 2 Acsbg2 4.3205 −1.5973
Acyl-CoA synthetase long-chain family member 4 Acsl4 5.6547 1.7361
Acyl-CoA synthetase long-chain family member 6 Acsl6 2.465 −1.5973
Acyl-CoA synthetase medium-chain family member 3 Acsm3 14.2353 5.697
Acyl-CoA synthetase medium-chain family member 4 Acsm4 6.1301 3.1806
Adiponectin, C1Q and collagen domain containing Adipoq −6.0324 3.2588
Apolipoprotein A-I Apoa1 4.2006 2.9178
Apolipoprotein B Apob 7.7651 −3.0228
Apolipoprotein E Apoe 4.4207 −1.0317
CD36 antigen Cd36 3.7512 1.7387
Carnitine palmitoyltransferase 1b, muscle Cpt1b 3.3366 2.0449
Fatty acid binding protein 3, muscle and heart Fabp3 2.7003 −1.5135
Lysophospholipase 1 Lypla1 3.5198 1.6047
Peroxisome proliferator activated receptor gamma Pparγ 8.3847 −1.6135
Stearoyl-Coenzyme A desaturase 1 Scd1 5.5982 1.0879
Solute carrier family 25, member 30 Slc25a30 2.6123 1.6634
Solute carrier family 27 (fatty acid transporter), member 1 Slc27a1 1.0514 −2.2919
Solute carrier family 27 (fatty acid transporter), member 3 Slc27a3 6.323 2.2207
Solute carrier family 27 (fatty acid transporter), member 5 Slc27a5 2.0184 −1.5973
Sterol regulatory element binding transcription factor 1 Srebf1 3.4573 −4.544
Sterol regulatory element binding factor 2 Srebf2 2.0208 −26.826
Very low density lipoprotein receptor Vldlr 2.0148 1.3077
Insulin resistance
V-akt murine thymoma viral oncogene homolog 1 Akt1 −2.2173 1.2477
Dynamin 1-like Dnm1l 1.4367 2.8522
Fas ligand (TNF superfamily, member 6) Faslg 4.8622 −1.4856
Insulin-like growth factor 1 Igf1 1.3447 2.4477
Mitogen-activated protein kinase kinase 1 Map2k1 2.3446 −2.1822
Phosphodiesterase 3B, cGMP-inhibited Pde3b 2.1481 1.5951
Protein kinase, cAMP dependent, catalytic, β Prkacb 1.687 2.4466
Protein kinase, AMP-activated, γ 1 non-catalytic subunit Prkag1 −2.6381 1.3516
Serpin peptidase inhibitor, clade B (ovalbumin), member 2 Serpinb2 −2.7789 1.8746
Serpin peptidase inhibitor, clade E
(nexin, plasminogen activator inhibitor type 1), member 1 Serpine1 46.1814 −1.4005
Superoxide dismutase 1, soluble Sod1 2.8805 1.0032
Superoxide dismutase 2, mitochondrial Sod2 −1.5522 3.1195
Uncoupling protein 1 (mitochondrial, proton carrier) Ucp1 58.6622 −1.7821
Vascular endothelial growth factor A Vegfa 2.0015 1.2082
Inflammation
CD3 antigen, epsilon polypeptide Cd3e 5.4019 1.3557
CD44 molecule Cd44 2.3883 1.322
Interleukin 3 Il3 2.3815 −1.1606
Interleukin 6 Il6 2.7362 1.9106
Janus kinase 2 Jak2 3.9723 1.721
Leptin receptor Lepr 7.2781 −1.6135
Selectin E Sele 13.8787 −1.5233
Suppressor of cytokine signalling 3 Socs3 4.5848 −2.4959
Tumor necrosis factor receptor superfamily, member 1b Tnfrsf1b 1.0099 −3.114
Tumor necrosis factor (ligand) superfamily, member 13 Tnfsf13 4.7142 1.2849
Tumor necrosis factor (ligand) superfamily, member 13b Tnfsf13b 2.0522 1.8583
Apoptosis
Bcl-2 binding component 3 Bbc3 −1.3703 −3.1586
B-cell CLL/lymphoma 2 Bcl2 −2.6947 1.8312
B-cell leukemia/lymphoma 2 related protein A1d Bcl2a1 −7.13 1.8085
Conserved helix-loop-helix ubiquitous kinase Chuk 4.2959 2.1502
Mitogen-activated protein kinase 3 Mapk3 1.2583 −3.0871
Optic atrophy 1 homolog (human) Opa1 1.3949 2.0255
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2.2.1. In Vitro Effect of Aspalathin on Fatty Acid and Lipid Metabolism
Data analysis identified 26 of the 57 (46%) differentially expressed genes to be involved in fatty
acid and lipid metabolism (Table 2). STRING network analysis identified three clusters encoding
interactive nodes representing genes associated with fatty acid/lipid transport, lipid metabolism and
fatty acid metabolism (confidence score, 0.7) (Figure 1).
Increased β-oxidation
Enhanced free fatty acid (FFA) uptake and lipid storage are causal factors known to precede the
development of diabetic heart failure [17–20]. In this study, we showed that high glucose increased
the expression of fatty acid transporters including cluster of differentiation 36 (CD36; 3.7-fold),
fatty acid-binding proteins 3 (Fabp3; 2.7-fold), solute carrier family 25, member 30 (Slc25a30;
2.6-fold) and solute carrier family 27, member 1, 3 and 5 (Slc27a1; 3 and 5 by 1.0, 6.3-fold and
2.0-fold, respectively) (Figure 1 and Table 2). This increased expression of fatty acid transport was
concomitant to raised expression levels of genes associated with β-oxidation including carnitine
palmitoyltransferase 1b (Cpt1b; 3.3-fold), acyl-CoA thioesterase 2 (Acot2; 2.8-fold), acyl-CoA oxidase 2
(Acox2; 2.0-fold), as well as lysophospholipase 1 (Lypla1; 3.5-fold) (Figure 1 and Table 2). Additionally,
we observed that high glucose exposure upregulated mRNA expression of stearoyl-CoA desaturase 1
(Scd1; 5.5-fold), an enzyme crucial for the synthesis and storage of fatty acids. However, aspalathin
treatment suppressed this effect, which was associated with reduced FFA uptake and oxidation
(Figure 1 and Table 2). This result was in agreement with our previous findings [10,21].
Increased Supply of Long-Chain Fatty Acids
Chronic hyperglycemia has been associated with an increased supply of circulating FFAs to
cardiomyocytes [10,21]. When this enhanced supply of FFAs exceed the rate of β-oxidation, myocardial
triglyceride accumulation occurs, leading to lipotoxicity [14,15]. Lipotoxicity subsequently leads to left
ventricular dysfunction, a major characteristic feature of DCM. A study done by Drosatos et al. [20]
showed that mice with cardiac-specific overexpression of acyl-CoA synthetase (Acsl) developed
lipotoxicity and diastolic dysfunction, directly implicating long-chain fatty acids (LCFAs) in the
development of cardiac fibrosis and subsequent myocardial remodeling [20]. Based on our dataset,
STRING analysis identified a network of genes with nodes linking long-chain fatty acyl-CoA
synthetase enzymes (Figure 1). These data confirm previous findings [20], where high glucose exposure
resulted in increased mRNA expression of acyl-CoA synthetase long-chain family member 4 and 6
(Acls4, 5.6-fold and Acls6, 2.4-fold) as well as acyl-CoA synthetase medium-chain family member 3
and 4 (Acsm3, 14.2-fold and Acsm4, 6.1-fold) (Figure 1 and Table 2). Results obtained showed that
aspalathin treatment was able to attenuate this effect.
Altered Lipid Metabolism and Increased Cholesterol Flux
Scientific evidence has shown that excessive cardiac lipid accumulation contributes to the
development of cardiac dysfunction [12,13,22,23]. Lipotoxicity in the myocardium has been associated
with the transcriptional factor sterol regulatory element-binding protein 1/2 (Srebf1/2) and the
transcriptional coactivator peroxisome proliferator-activated receptor-γ (PPARγ) [20,22]. Srebf1/2 and
PPARγ are important switches that regulate lipid accumulation and lipotoxicity. In a study done
by Marfella et al. [15] on biopsies from diabetic patients with left ventricular dysfunction, increased
cardiac lipid deposits were concomitant with enhanced mRNA expression of Srebf1/2, PPARγ as
well as genes associated with accelerated β-oxidation. Notably, in this study, elevated levels of
circulating FFAs were observed after high glucose exposure. This was parallel to enhanced mRNA
expression of Srebf1/2 (3.4 and 2.0-fold, respectively), as well as PPARγ (8.3-fold) (Figure 1 and Table 2).
Increased expression of Srebf1 is further linked to the development of an atherogenic apolipoprotein
profile, a characteristic of cardiac hypertrophy [24,25]. Apolipoproteins play an important role in
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the regulation of lipoprotein metabolism, with the main function being the transport of triglycerides
and cholesterol through the lymphatic and circulatory systems. [25]. In particular, Apoa1 is the major
protein component of HDL. HDL promotes efflux of cholesterol, phospholipids, and other lipophilic
molecules from cells by an active process mediated by a cell-membrane transporter, ATP-binding
cassette transporter (Abca1) [23,25]. By contrast, apolipoprotein B (Apob) is the main apolipoprotein
of chylomicrons and LDL. Elevated LDL levels have been associated with an increased risk of heart
failure [23,25].
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In this study, we observed an increased mRNA expression of Apob (7.7-fold), apolipoprotein E
(Apoe; 4.4-fold) and very low-density lipoprotein (Vldlr; 2.0-fold) that was decreased after aspalathin
treatment (Figure 1). Like increased HDL cholesterol in Leprdb/db mice, Apoa1 and its transporter Abca1
were increased by 4.2-fold and 2.0-fold, respectively, after high glucose exposure. Aspalathin treatment
reversed this effect. Furthermore, this study showed that high glucose exposure resulted in the reduced
expression of Adipoq (-6.0-fold), while aspalathin was able to reverse this effect. Cardiac lipotoxicity
caused by chronic hyperglycemia may lead to the development of cardiac fibrosis [25–27]. We observed
that aspalathin treatment was able to reverse lipotoxicity by modulating key regulatory genes, such as
Adipoq, PPARγ and Sreb1/2 (Figure 1). We propose that aspalathin can prevent lipid accumulation by
increasing the expression of Adipoq. This increase is associated with a reduced PPARγ and Srebf1/2
expression which may cause lipid accumulation in H9c2 cardiomyocytes. This data was parallel to the
observed reduction in systemic total cholesterol, triglycerides and low-density lipoprotein in Leprdb/db
mice (Figure 1 and Table 2).
2.2.2. In Vitro Effect of Aspalathin on the Development of Insulin Resistance
It is well described that increased LCFAs result in the intramyocardial accumulation of
diacylglycerol that activates protein kinase C (θ isoform), leading to the inhibition of insulin receptor
substrate 1 and the development of an insulin resistant phenotype [10–12]. The latter can reduce
cardiac performance as the heart is an insulin-responsive organ. Data analysis revealed that 14 (25%) of
the 57 differentially expressed genes were associated with the development of hyperglycemic-induced
insulin resistance (Table 2). Network mapping of the differential expressed genes identified two major
interconnecting clusters (genes associated with protein kinase activity and development of insulin
resistance) with serine/threonine-protein kinase homolog 1 (Akt1) and mitogen activated protein
kinase (Mapk) being the major nodes of connection (confidence score 0.7) (Figure 2).
Insulin Signaling and Effect on Myocardium
Akt1 is a pro-survival protein kinase that plays an important role in the regulation of various
cellular functions, including metabolism (glucose and lipids), growth, migration, proliferation and cell
survival [28]. STRING network analysis identified Akt1 as the central node associated with 12 of the 14
differentially expressed genes. Akt1 constitutes an important node with diverse signaling cascades.
In this study, a direct link was observed between phosphodiesterase 3B (Pde3b) and Akt1. Studies have
demonstrated that cAMP-dependent protein kinase signaling is impaired in diabetes and is associated
with cardiac dysfunction [29,30]. Cyclic AMP (cAMP) plays a significant role in the thermogenic
process, as well as in potentiating glucose-stimulated insulin release [29,30]. In contrast, Pde3b is
a negative regulator of cAMP and increased expression of this gene inhibits or diminishes the effect of
cAMP [23]. Pde3b is highly expressed in the myocardium and is known to decrease myocardial smooth
muscle contractility [31]. In studies done on isolated rat islets, inhibition of Pde3b was reported to
improve insulin release [32,33]. In the present study, high glucose exposure resulted in the upregulation
of Pde3b by 2.1-fold (Figure 1 and Table 2). However, treatment with aspalathin was able to reverse
this response. Furthermore, Akt1 was found to be associated with various antioxidant genes including
superoxide dismutase 2 (Sod2) and uncoupling protein 1 (Ucp1). Aspalathin increased Sod2 (3.1-fold)
expression while the effect of high glucose on Ucp1 (-1.7-fold) expression was decreased (Figure 2).
Interestingly, in a study done by Barreto et al. [34], investigating the mechanism of Ucp1 action on
stress response, they observed that increased Ucp1 expression induced the upregulation of various
antioxidant stress-response genes. We speculate that the observed increased Ucp1 expression could be
a compensatory mechanism used by the cells to ameliorate the adverse effects of increased FFA and
hyperglycemia-induced reactive oxygen species (ROS).
Impaired myocardial substrate preference, induced by aberrant FFA levels and insulin resistance,
activates a myriad of other maladaptive signaling pathways. Insulin-like growth factor 1 (Igf1) activates
and phosphorylates Akt1 to attenuate the development of diabetes-induced myocardial apoptosis,
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by inhibiting tumor suppressor protein 53 [35,36]. In this study, high glucose had no effect on the
expression of Igf1, but decreased Akt1 mRNA expression (-2.2-fold) (Figure 2). Conversely, the tumor
necrosis factor ligand superfamily member 6 (Faslg) that interacts with Akt1, has been shown to induce
apoptosis through binding and inhibiting the pro-survival gene CASP8 and FADD-like apoptosis
regulator (Cflar) [37]. In this study, high glucose treatment increased mRNA expression of Faslg
(4.8-fold), while aspalathin prevented this response. Thus, our results infer that aspalathin protected
cardiomyocytes exposed to chronic hyperglycemia against Faslg-induced apoptosis by activating
the Igf-PI3K-Akt pro-survival pathway (Figure 2). Additionally, STRING data analysis showed
that an interactive network was formed between Igf1, Akt1, serpin peptidase inhibitor, member 1/2
(Serpin1/2) and vascular endothelial growth factor A (Vegfa) (Figure 2).
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Figure 2. Aspalathin prevented high glucose-induced insulin resistance. (A) STRING database analysis
confirmed a strong interaction between aspalathin treatment and genes associated with insulin
resistance; (B) Representative diagram of the proposed protective mechanism of aspalathin against
insulin resistance and resultant oxidative stress. Akt1: v-akt murine thymoma viral oncogene homolog 1;
cAMP: cyclic adenosine monophosphate; Dnm1l: dynamin 1-like; Faslg: fas ligand (TNF superfamily,
member 6); Igf : insulin-like growth factor 1; Map2k1: mitogen-activated protein kinase kinase 1; Pde3b:
phosphodiesterase 3B; Prkag: protein kinase, AMP-activated, γ 1 non-catalytic subunit; Serpine1: serpin
peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1; Sod2: superoxide
dismutase 2; Ucp1: uncoupling protein 1; Vegfa: vascular endothelial growth factor A.
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High glucose treatment resulted in a 2.0-fold increased expression of Vegfa, while reducing
expression of Serpinb2 and Serpine1 by -2.7 and -46.1-fold, respectively (Figure 2 and Table 2).
However, we proposed that the observed increased expression of Serpine1 might lead to
cardioprotection; however, this hypothesis requires further investigation as the regulation of Serpin1 is
controversial [38–40].
Protein Kinases and Mitochondrial Function
Damaged structural components of the heart, caused by insulin resistance, activate signaling
pathways such as p38 mitogen-activated protein kinases (Mapk) [41]. STRING network analysis
identified three distinct nodes within this network, including dynamin 1-like (Dnm1l), Map2k1
and cAMP-dependent protein kinase catalytic subunit (Prkacb), that are involved in the process of
mitophagy [42]. Roy et al. [43] showed that mice lacking Dnm1l demonstrate impaired heart contraction
with an associated reduction in mitochondrial fission, concluding that Dnm1l is critical for sustaining
mitochondrial morphology and heart function. Interestingly, Dnm1l levels were increased 2.8-fold
after aspalathin treatment.
Mitophagy induction can also be regulated/activated through the Prka-MTOR-ULK1 mediated
signaling pathway [43]. STRING analysis showed a strong interaction between protein kinase,
AMP-activated, γ 1 non-catalytic subunit (Prkag) and Mapk. In this study we observed that high
glucose resulted in the enhanced expression of Map2k1 (2.3-fold), with an associated decrease in the
mitophagy activator Prkag1 expression (-2.6 fold). However, aspalathin treatment reversed this effect
(Figure 2). Thus, we speculate that aspalathin might possibly protect the myocardium from chronic
hyperglycemia through enhanced cAMP-mediated mitophagy, thereby alleviating FFA-induced MAPK
toxicity and subsequent intracellular lipid accumulation in vitro [44].
2.2.3. In Vitro Effect of Aspalathin on Inflammation
In a diabetic state, a complex interplay between impaired cardiac substrate metabolism,
insulin resistance and inflammation underlies the progression of the DCM. Furthermore, evidence
is accumulating on the important role of inflammation in the development of cardiac hypertrophy
and failure. Aberrant and/or prolonged suppression of cytokine signaling (Socs) proteins and Janus
kinase (JAK) -induced signaling is detrimental and can give rise to a number of inflammatory
pathologies known to affect cardiac function [45,46]. Accordingly, 11 of the 57 (19%) differentially
expressed genes were associated with cytokine signaling (Table 2). STRING analysis identified
a network with five distinct nodes that include interleukins, Cd3e antigen (Cd3e), Socs3, and leptin
receptor precursor (Lepr), with JAK2 (Jak2) being the predominant interactive node (Figure 3).
Leptin Signaling
Leptin is an adipokine predominantly expressed in adipose tissue, but it is also expressed in
cardiac heart muscle cells [17]. Accumulative evidence suggests that leptin impairs myocardial
energy metabolism by favoring a complete reliance on FFAs as an energy source leading to cardiac
hypertrophy [17,45]. Leptin binding to the leptin receptor activates the JAK/Signal Transducers and
Activators of Transcription (STAT) pathway. Activation of this pathway results in the translocation of
STAT to the nucleus where it can activate Socs3, inhibiting leptin action, as well as insulin signaling [46].
A meta-analysis of our data showed that Lepr expression was increased (7.2-fold) after high glucose
treatment. Interestingly, this increase was concomitant with an increase in the mRNA expression of
both Jak2 (3.9-fold) and Socs3 (4.5-fold). This result is of interest, as increased Lepr expression is known
to enhance Socs3 with an associated altered β-oxidation [46].
Cytokine Signaling
In the diabetic heart, increased lipotoxicity and insulin resistance trigger the recruitment of
macrophages and leukocytes before the release of pro-inflammatory cytokines such as interleukin 3 and
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6 (Il3 and Il6), tumor necrosis factor superfamily (Tnf ) and cluster of differentiation (Cd). Il6, Tnf and
Cd cause the endothelial cells of blood vessels to express cellular adhesion molecules, such as Selectin E
(Sele) and CD4 antigen (Cd44), resulting in an acute localized cellular inflammation. Both CD44 and Sele
are cell-surface glycoproteins that mediate neutrophil, monocyte, lymphocyte and platelet rolling in the
ventricular wall. These glycoproteins also play an important role in atherosclerotic lesion development
and calcification of the lesion [47,48]. Studies demonstrated that Cd44, as well as Sele null mice display
atherosclerosis plaque formation [47,48]. Our results showed that high glucose treatment increased
the expression of various pro-inflammatory cytokines including, Il3 (2.3-fold), Il6 (2.7-fold), Tnsf13
(4.7-fold) and Tnfsf13b (2.1-fold), Sele (13.8-fold) and Cd44 (2.3-fold) (Figure 3 and Table 2). Based on
our gene expression data, we propose that during chronic hyperglycemia, pro-inflammatory cytokines
(Il3, Il6 and Tnf-α) are activated. This increased inflammatory cytokine response releases Sele and Cd44
from the storage granules in activated platelet and endothelial cells and recruits them to mediate the
first step of leukocyte extravasation. Additionally, Il6 and Tnf activate the JAK/STAT and Map kinase
pathways respectively, resulting in increased hypertrophy and apoptosis. Increased expression of Socs3
has been linked to inflammation-induced insulin resistance and enhanced JAK/STAT signaling [49].
As observed in this study aspalathin treatment was able to reverse this effect (Figure 3).
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2.2.4. In Vitro Effect of Aspalathin on Apoptosis
Chronic hyperglycemia, insulin resistance and inflammation exacerbates oxidative stress and
cardiomyocyte apoptosis [18,21]. In this study, six of the 57 (11%) differentially expressed genes were
associated with apoptosis signaling (Table 2). STRING data analysis identified one network with
five interactive nodes, centralized around the B-cell lymphoma 2 gene (Bcl2).
Genes identified in this network included Bcl2, Bcl2 binding component 3 (Bbc3), mitogen activated
protein kinase 3 (Mapk3) and optic atrophy 1 homolog (Opa1) (Figure 4 and Table 2). The Bcl2 family
of proteins are known to be strong modulators of apoptosis and can induce either pro-apoptosis or
cell survival depending on the cell’s fate [10,21]. Two pro-survival genes reduced after high glucose
exposure were identified (Bcl2 and Bcl2a1). Four pro-apoptotic proteins (Bbc3, Chuk, Mapk3 and Opa1)
were identified (Figure 4 and Table 2). Activation of Mapk3 together with pro-apoptotic proteins such
as Bbc3 has been associated with myocardial dysfunction [18,50], while upregulation of Opa1 has
directly been linked to the reversal of mitochondrial apoptosis [18,50,51]. Interestingly, aspalathin
treatment at a high dose was able to ameliorate this effect by increasing the expression of survival genes.
Thus, from this result we proposed that Bcl2 is the main regulatory network used by aspalathin to
protect the myocardium against hyperglycemic-induced cell apoptosis.
Molecules 2017, 22, 219  11 of 17 
 
2.2.4. In Vitro Effect of Aspalathin on Apoptosis 
Chronic hyperglycemia, insulin resistance and inflammation exacerbates oxidative stress and 
cardiomyocyte a optosis [18,21]. In this tudy, six of the 57 (11%) differentially expressed gen  were 
associated with apoptosis signaling (Table 2). STRING data analysis identified one network with fiv  
interactive nodes, cen ralized around the B-cell lymphoma 2 ge e (Bcl2). 
Genes id tifi d in his network included Bcl2, Bcl2 binding component 3 (Bbc3), mitogen 
activat d protein kinase 3 (Mapk3) and optic atrophy 1 homolog (Opa1) (Figure 4 and Table 2). The 
Bcl2 family of proteins are known to be strong dulators of apoptosis and can induc  either pro-
apoptosis or cell survival depending n the cell’s f te [10,21]. Two pro-s rvival genes reduced afte  
high glucose exposure were identified (Bcl2 and Bcl2a1). Four pro-apoptotic proteins (Bbc3, Chuk, 
Mapk3 and Opa1) wer  identifie  (Figure 4 and Table 2). Activation of Mapk3 together with pro-
apoptotic proteins such s Bbc3 has been ssociated with myocardial dysfuncti n [18,50], while 
upregulation of Opa1 has directly been linked to the reversal of mitochondrial apoptosis [18,50,51]. 
Int restingly, aspalathin treatment at a high d se w s ble t  ameliorate this effect by increasing the 
expression of survival genes. Thus, from this result we proposed that Bcl2 i  the main regulatory 
network used by aspalathin to protect the myoc rdium gainst hyperglycemic-induced cell 
ap ptosis. 
 
Figure 4. Aspalathin limited high glucose-induced apoptosis. STRING database analysis confirmed a 
strong interaction between genes associated with aspalathin treatment and regulation of high glucose 
induced apoptosis.  
2.3. Limitations to This Study 
Due to tissue limitation, we were unable to test the effect of aspalathin on lipotoxicity markers 
in heart tissue from Leprdb/db mice. However, transcriptional regulation was performed on H9c2 
cardiomyocytes, which is an acceptable model to investigate metabolic and signaling alterations 
associated with cardiac dysfunction. 
3. Materials and Methods  
3.1. Reagents and Kits 
Pure aspalathin (ca. 98%, batch SZI-356-54) was synthesized by High Force Research (Durham, 
UK) according to a previously published protocol [52]. H9c2 rat derived cardiomyoblasts were 
purchased from the European Collection of Cell Cultures (ECACC No. 8809294; Wiltshire, UK). 
Radioimmunoassay insulin kit was obtained from Linco Research (St. Charles, MO, USA), halothane 
from Safeline Pharmaceuticals (Johannesburg, South Africa), Dulbecco’s Modified Eagle’s Medium, 
penicillin, and streptomycin from Lonza (Verviers, Belgium), and fetal bovine serum sourced from 
Figure 4. Aspalathin limited high glucose-induced apoptosis. STRING database analysis confirmed
a strong interaction between genes associated with aspalathin treat ent and regulation of high glucose
induced apoptosis.
2.3. Limitations to This Study
Due to tissue limitation, we were unable to test the effect of aspalathin on lipotoxicity markers
in heart tissue from Leprdb/db mice. However, transcriptional regulation was performed on H9c2
cardiomyocytes, which is an acceptable model to investigate metabolic and signaling alterations
associated with cardiac dysfunction.
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(Durham, UK) according t a previously published protocol [5 ]. H9c2 rat erived cardiomyoblasts
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penicillin, and streptomycin from Lonza (Verviers, Belgium), and fetal bovine serum sourced from
Biochrom (Berlin, Germany). The RNeasy Mini Kit, RT2 First Strand Kit, RT2 Profiler PCR Arrays and
RT2 SYBR Green, qPCR Master Mix were obtained from Qiagen (Valencia, CA, USA), while the
TRIzol reagent and Turbo DNase Kit were from ThermoFisher Scientific (Waltham, MS, USA).
All other consumables and reagents were purchased from Sigma-Aldrich Corp. (St. Louis, MO, USA),
unless otherwise specified.
3.2. Animal Ethics
Male C57BLKS/J homozygous Leprdb/db mice and their heterozygous leptin-receptor-deficient
nondiabetic lean littermate controls Leprdb/+ were obtained from Jackson’s Laboratories (Sacramento,
CA, USA) and housed at the Primate Unit and Delft Animal Centre (PUDAC) of the South African
Medical Research Council (SAMRC) in a controlled environment with a 12 h light/dark cycle in
a temperature range of 23–25 ◦C (relative humidity: ~50%). The mice received standard laboratory
chow pellets (Afresh Vention, Cape Town, South Africa ) ad libitum and had free access to drinking water.
The study was performed according to principles and guidelines of the South African Medical Research
Council’s Guidelines on Ethics for Medical Research: Use of Animals in Research and Training,
2004 (http://ww.mrc.ac.za/ethics/ethicsbook3.pdf) under the institutional ethical approval of the
SAMRC (ECRA No. 07/13) as well as Stellenbosch University Ethics Committee (SU-ACUM13-00021).
3.3. Aspalathin Treatment of Mice
For this study, animal experiments were only performed to assess the effect of aspalathin on
blood lipid profiles. H9c2 cells, as an isolated cell-based system, were used to directly test the effect
of aspalathin on the myocardium without the influence of any variables that would be introduced
when using an animal model. Following acclimatizing for one week, nine-week old Leprdb/db mice
together with Leprdb/+ (n = 6 per group) control mice were randomly divided into five groups.
Mice were treated daily for six weeks through oral gavage with either a low (13 mg/kg/day) or high
(130 mg/kg/day) aspalathin dose and compared to metformin (150 mg/kg/day). Treatment dosages
were calculated based on a published study [8]. Treatment groups included: (i) Leprdb/+ untreated
controls (Leprdb/+_UC); (ii) Leprdb/db untreated controls (Leprdb/db_UC); (iii) Leprdb/db treated with
metformin (Leprdb/db_MET); (iv) Leprdb/db treated with low dose aspalathin (Leprdb/db_ASP_LD) and (v)
Leprdb/db treated with high dose aspalathin (Leprdb/db_ASP_HD). Aspalathin and metformin were
dissolved in distilled water before orally administration at the same time (08:00–09:00 a.m.) every day
for six weeks, while untreated animals were given water in place of treatment.
3.4. Effect of Aspalathin on HOMA-IR
Mice were fasted for 4 h before plasma glucose levels were measured on a weekly basis
by tail pricks using an OneTouch Select handheld glucometer (LifeScan, Milpitas, CA, USA).
Fasting plasma insulin was determined using the Radioimmunoassay Kit, as per manufacturer’s
instruction. HOMA-IR was calculated using FPG and insulin values, according to a previous described
method [53].
3.5. Effect of Aspalathin on Lipid Profiles
After the six-week treatment period, 4 h fasted mice were weighed and anesthetized
with halothane before blood was collected from the abdominal vena cava for subsequent lipid
profile analysis. Blood was centrifuged at 4000× g at 4 ◦C for 15 min before the serum was removed
and sent to PathCare Medical Diagnostic Laboratories (Cape Town, South Africa) for total cholesterol,
triglycerides, LDL, and high-density lipoprotein (HDL) analyses.
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3.6. Cell Culture and Treatment of H9c2 Cardiomyocytes with Aspalathin for Subsequent RT2 PCR Profiler
Array Analysis
Embryonic ventricular rat heart-derived H9c2 cardiomyoblasts were cultured in supplemented
Dulbecco’s Modified Eagle’s Medium (10% fetal bovine serum, 100 U/mL of penicillin, 100 µg/mL of
streptomycin) for 48 h under standard tissue culture conditions (37 ◦C in humidified air and 5% CO2).
Confluent cells (60%–80%) were seeded at a density of 2 × 104 in 6-well multi-plates. Thereafter, H9c2
cardiomyoblasts were differentiated into adult cardiomyocytes for 7 days using retinoic acid according
to a previously described method [54]. On day 8, H9c2 cells were exposed to 33 mM glucose for 48 h
and then treated with or without aspalathin (1 µM) for an additional 6 h. Cells exposed to 5.5 mM
glucose were used as a normal glucose control [10].
3.7. RT2-PCR Array Analysis of H9c2 Cells Treated with and without Aspalathin
Total RNA from three biological experiments (each with three technical replicates) was extracted
using TRIzol reagent, according to a previously described protocol [10]. RNA was purified using
the RNeasy Mini Kit (Qiagen, Hilden, Germany), while the Turbo DNase Kit (Ambion, Austin,
TX, USA) was used to remove genomic DNA, as per manufacturer’s instructions. RNA integrity
was determined using an Agilent 2100 Bioanalyser (Agilent Technologies, Palo Alto, CA, USA).
RNA from three independent experiments were pooled and cDNA was synthesized from 2 µg of pooled
RNA using the RT2 First Strand Kit, according to manufacturer’s instructions. Rat Atherosclerosis
(PARN-038ZA-2), Cytokine (PARN-011ZA-2), Fatty Acid Metabolism (PARN-007Z), and Insulin
Resistance (PARN-156ZA-2) RT2 Profiler PCR Arrays were used for mRNA profiling studies using
ABI7500 (ThermoFisher Scientific, Waltham, MA, USA). Analysis of PCR array data was done according
to manufacturer’s instructions, using a Microsoft Excel macro available from the manufacturer
(http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php). Each array contained five
housekeeping genes (Actb, B2m, Gapdh, Gusb and Hsp90ab1) against which the sample data
were normalized. The transcript level of each candidate gene was quantified according to the
∆∆Ct method. Ct values > 35 were not included in the analysis and considered as negative.
3.8. Gene Interaction and Network Analysis
Search Tool for the Retrieval of Interacting Genes/Proteins (STRING; http://string-db.org/)
database was used for gene interaction and network analysis to represent information of known and
anticipated gene interactions [55,56]. A STRING analysis confidence score of 0.7 was used as a cut off.
3.9. Statistical Analysis
Data were expressed as the mean ± SEM. Results for in vitro experiments were expressed as
the mean of three independent biological experiments with each experiment containing at least three
technical replicates, unless otherwise stated. For in vivo experiments, each treatment group contained
six mice. Statistical analysis was performed using GraphPad Prism software version 5.0 (GraphPad
Software, Inc., La Jolla, CA, USA). Comparisons between groups were performed using one-way
multivariate ANOVA, followed by unpaired Student t-test, and a p-value of ≤0.05 was designated as
statistically significant.
4. Conclusions
Results obtained in this study lead us to propose that aspalathin could protect the myocardium
against lipotoxicity in two ways. In the first instance, such treatment significantly improves the
blood lipid profile to a far less damaging one therefore attenuating fuel substrate availability to
the diabetic heart. It is likely that aspalathin mediates such effects by acting on targets in the liver,
although this was not further investigated in the current study. Secondly, our data demonstrate
that aspalathin also exerts direct, protective effects within the myocardium to protect the heart
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against excess fuel substrate availability. Here, our data indicate that aspalathin may protect the
myocardium against lipotoxicity and subsequent cell apoptosis by increasing the expression of
Adipoq and subsequently decreasing the expression of CD36 and Cpt1. Furthermore, aspalathin
reduced lipid transport via Slc27a3/5, which together with reduced PPARγ and Srebf1 resulted in
decreased total cholesterol and subsequent cell apoptosis. Moreover, we proposed that the reversal of
lipotoxicity results in a decreased inflammatory response via the Il6/Jak/Stat pathway, which together
with an observed increase in Bcl2 prevents myocardium cell apoptosis. Together, these findings
proposed a probable mechanism by which aspalathin reverses metabolic abnormalities associated with
the failing myocardium. However, this warrants further investigation.
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